Neomorph Doses First Patient in Phase 1/2 Trial of NEO-811 Molecular Glue Degrader for Advanced Renal Cell Carcinoma
核心洞察
Neomorph (搜索) has dosed the first patient in a Phase 1/2 clinical trial evaluating NEO-811 (搜索), a novel molecular glue degrader, for locally advanced or metastatic non-resectable clear cell renal cell carcinoma (搜索).
NEO-811 (搜索) represents the first clinical evaluation of an asset from Neomorph (搜索)'s internally developed pipeline, marking a pivotal milestone for the company's molecular glue degrader platform.
The investigational drug is designed to induce targeted degradation of a key disease-driving protein and fully block a central signaling pathway implicated in clear cell renal cell carcinoma (搜索).
Neomorph (搜索), Inc. has achieved a significant milestone by dosing the first patient in its Phase 1/2 clinical trial evaluating NEO-811 (搜索), a novel investigational molecular glue degrader, for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (搜索) (ccRCC (搜索)). The trial initiation represents the first clinical evaluation of an asset from the company's internally developed pipeline.
Clinical Trial Design and Objectives
The Phase 1/2 NEO-811 (搜索)-101 trial (NCT07300241) is structured as a first-in-human, open-label study consisting of a single agent dose-escalation phase followed by dose expansion cohorts. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of NEO-811 in patients with locally advanced or metastatic non-resectable ccRCC (搜索).
"Dosing the first patient in our Phase 1/2 trial of NEO-811 (搜索) in renal cell carcinoma (搜索) marks a pivotal inflection point for Neomorph (搜索), representing the first clinical evaluation of an asset from our internally developed pipeline," said Phil Chamberlain, DPhil., Co-Founder, President, and Chief Executive Officer of Neomorph. "As we advance in the clinic, we look forward to generating data that will inform the continued development of NEO-811 and further validate the potential of our platform to deliver differentiated medicines for patients with significant unmet need."
Novel Mechanism of Action
NEO-811 (搜索) is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signaling pathway implicated in ccRCC (搜索). The drug leverages a differentiated degradation mechanism that has the potential to address underlying tumor biology that remains inadequately treated with current standards of care.
Toni Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and chair of the study steering committee, emphasized the therapeutic potential of this approach. "NEO-811 (搜索) is a novel, potent, cereblon (搜索)-dependent, and selective molecular glue degrader designed to fully block a key signaling pathway in clear cell renal cell cancer. The unique mechanism of action of NEO-811 is quite promising and could offer a new treatment option for patients."
Platform Technology and Company Background
Neomorph (搜索) positions itself as a leader in molecular glue technology, having created what the company describes as the world's largest proprietary molecular glue target space. This spans multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases (搜索). The company's approach involves engineering neomorphic protein surfaces to enable precision targeted protein degradation of disease drivers that have historically been considered undruggable.
The biotechnology company was founded in 2020 and is venture-backed by Deerfield Management Company (搜索). NEO-811 (搜索) is currently being evaluated as a monotherapy in the first-in-human Phase 1/2 clinical trial targeting patients with locally advanced or metastatic non-resectable ccRCC (搜索).